MSC‐Derived Exosomes Alleviate Intestinal Barrier Injury in an IBD‐on‐a‐Chip
Biotechnology Journal · 2025
DOI: 10.1002/biot.70081 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology Journal, 2025. Verfasst von Yingying Xie und 6 weiteren Autor:innen. Beteiligte Einrichtung: Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China. Hauptthemen laut MEDLINE: Exosomes, Mesenchymal Stem Cells, Inflammatory Bowel Diseases, Lab-On-A-Chip Devices. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: National Key R&D Program of China, National Nature Science Foundation of China, Space Application System of China Manned Space Program.
Abstract (Originalsprache)
Inflammatory bowel disease (IBD) is a chronic, nonspecific inflammatory condition affecting the colon or gastrointestinal tract, with an unknown etiology. Given the unclear pathogenesis, the development of preclinical models becomes particularly crucial for reflecting its pathological features and supporting effective therapies. In this study, we developed a pumpless IBD‐on‐a‐chip model that allows to replicate the key pathological changes of IBD, including intestinal barrier disruption, intestinal villus destruction, macrophage polarization, inflammatory response, and vascular endothelial detachment. This model was utilized to evaluate the therapeutic effects of 5‐Amino Salicylic Acid (5‐ASA) and mesenchymal stem cell (MSC)‐derived exosomes (MSC‐Exos). The results demonstrated that both 5‐ASA and MSC‐Exos could relieve intestinal damage by protecting the villous structure. Additionally, we discovered that MSC‐Exos could suppress inflammatory responses on the chip by inducing macrophage differentiation toward the M2 phenotype, while transcriptomic analysis revealed both activation and inhibition of specific inflammation‐related pathways. This study presents the first application of an IBD‐on‐a‐chip model to evaluate the therapeutic efficacy of MSC‐Exos, highlighting its potential for advancing new therapeutic strategies for this debilitating disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China.
- University of Chinese Academy of Sciences, Beijing, China.
- First Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian, China.
- University of Science and Technology of China, Hefei, China.
- Suzhou Institute for Advanced Research, University of Science and Technology of China, Suzhou, China.
ORCID-Profile: Xu Zhang, Jianhua Qin
Förderung
- National Key R&D Program of China
- National Nature Science Foundation of China
- Space Application System of China Manned Space Program
- Dalian Science and technology Innovation Fund project
- Innovation Program of Science and Research from the DICP, CAS
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Xie, Y., Guan, X., Liu, M., Tan, T., Zhang, M., Zhang, X., & Qin, J. (2025). MSC‐Derived Exosomes Alleviate Intestinal Barrier Injury in an IBD‐on‐a‐Chip. Biotechnology Journal. https://doi.org/10.1002/biot.70081
Vancouver
Xie Y, Guan X, Liu M, Tan T, Zhang M, Zhang X, et al. MSC‐Derived Exosomes Alleviate Intestinal Barrier Injury in an IBD‐on‐a‐Chip. Biotechnology Journal. 2025. doi:10.1002/biot.70081
BibTeX
@article{Xie2025,
author = {Xie, Yingying and Guan, Xiuli and Liu, Mingxian and Tan, Tiantian and Zhang, Min and Zhang, Xu and Qin, Jianhua},
title = {MSC‐Derived Exosomes Alleviate Intestinal Barrier Injury in an IBD‐on‐a‐Chip},
journal = {Biotechnology Journal},
year = {2025},
doi = {10.1002/biot.70081}
}
EUVIMED